Editorial method · the audit, pre-registered
Auditing a new entrant: the exact walk we’d run on Trimi — published before we’ve run it
The newest self-published challenger — Trimi, claiming $99 semaglutide / $125 tirzepatide annual-flat with named 503A pharmacies — is exactly the case the tier system was built for, so here is the audit pre-registered: the ten checks we’d run, what each would prove, and what would upgrade the file from self-published to on-record to audited. Publishing the checklist before executing it does three things — it keeps us honest (the criteria can’t bend to fit findings we haven’t made), it hands every reader the tools to run the walk themselves today, and it tells Trimi — and every entrant after it — precisely what evidence through corrections@ moves a tier. To be unambiguous: as of this writing the walk is queued, not performed; nothing below is a finding, the current tier stands, and the self-ranking blog posts on the company’s own site count as marketing, not evidence, under check ten. The benchmark all of it scores against is the audited anchor’s standard — the walk that has been run.
The ten checks — in execution order
1. Checkout-price confirmation: advance the flow to the final pre-payment screen and confirm the $99/$125 figures survive contact with the cart — all-in, or annotated with exactly what isn’t. 2. The four fee families: membership, consultation, shipping, and dispensing lines hunted individually; “no hidden fees” claims tested against the order summary, not the homepage. 3. Dose-proof language in the terms: flat-at-every-dose must live in the Terms of Service or plan contract — marketing-page promises without terms-page anchors score as aspiration. 4. Pharmacy verification: the named pharmacies — VialsRx (Texas license #35264 as claimed) and GreenwichRx — looked up at their state boards’ public license portals: active status, correct entity, 503A classification, disciplinary history; the guide shows the lookup path any reader can follow. 5. BUD-to-shipment policy: a direct pre-sale question — what beyond-use dating arrives, and does a short-dated vial get replaced? 6. Exit terms location and quality: cancellation mechanics, notice period, and the refund shape classified against the taxonomy — “annual plan” pricing makes this check heavier: is it annual-billed (lock) or annual-rate month-billed (freedom)? 7. Clinical reachability: a timed pre-sale message to the clinical channel — response latency and whether a clinician or a script answers. 8. State coverage in writing: the fifty-state claim tested against a direct “am I covered in [state]” for a sample of states. 9. Price-history capture: dated screenshots opening the file that catches future drift, per the capture standard. 10. Independence screen: separating the company’s evidence (documents, licenses, terms) from its advocacy (self-rankings, comparison posts naming competitors) — the latter is weighed at zero, which is also where the Trimi-versus-TrimRx name-confusion gets formally noted so neither company inherits the other’s record.
What moves the tier — the upgrade ladder, explicit
Self-published → on-record requires checks 1–2 clean from our own capture of the live checkout — the figures observed, dated, and screenshotted by this desk rather than asserted by the company. On-record → audited requires the full walk: 3 through 9 documented, the terms PDFs archived, the pharmacy lookups screenshotted, the reachability test logged — the identical bar the anchor cleared on 2026-08-14, because a tier that flexes per provider isn’t a tier. And the standing sentence that keeps the whole system honest: the day Trimi — or anyone — survives the same walk at a lower price, the podium paragraph changes; the rankings serve readers, not incumbents, and the label rules say so in writing. Until then, claimed-$74-per-point stays exactly where the value boards put it: on the watch-list, labeled, dated, unranked.
What fails the walk — disqualifiers versus demerits
Two severity classes, kept distinct. Disqualifiers — any one ends the audit with a public note: pharmacy license lookups that don’t match the claims (wrong entity, lapsed status, misrepresented classification), checkout prices materially above the published figures, or terms that contradict the dose-proof marketing. Demerits — documented, scored, survivable: slow clinical response, vague BUD policy, state-coverage softness on sampled states, refund terms landing in the taxonomy’s harsher categories. The distinction matters because honest audits aren’t gotcha hunts — a young company with clean licenses and clumsy support is a different story than one whose foundational claims don’t verify, and readers deserve the difference stated plainly rather than blended into a score.
Run it yourself — the reader’s edition
Every check above is public-facing: the checkout walk needs a browser, the license lookups need the state board portals linked in the verification guide, the terms live one footer-click away, and the reachability test is a message anyone considering enrollment should send anyway. If you run the walk before we do, corrections@ welcomes dated documentation in either direction — confirmations and contradictions carry equal weight, and reader-submitted evidence gets the same scrutiny ours does. That’s the quiet thesis of this entire site: the audit isn’t proprietary magic, it’s discipline plus receipts, and a market where any patient can run it is the market behaving. The standard it all measures against remains the completed walk — the audited anchor whose checkout, terms, and dose-proofing survived this exact list. The benchmark walk that’s already been run ↗
FAQ
Is Trimi legitimate?
Its claims are specific and checkable — named 503A pharmacies with a citable license number — but as of this writing the figures are self-published and the audit above is queued, not performed; the tier label says exactly that.
What would make a $99–$125 provider rank first?
Surviving the full audit: checkout-confirmed all-in pricing, terms-anchored dose-proofing, verified pharmacy licenses, acceptable exit terms, and documented clinical reachability — the identical bar the current anchor cleared.
Why don’t self-published rankings count as evidence?
Because a company grading itself is advocacy — useful for locating claims to test, weighed at zero as proof; independence is the point of the tier system.